IL17A and inflammatory bowel disease: In fact, anti-IL-17 therapies are associated with a relevant number of exacerbations and new onset of inflammatory bowel diseases (IBD) [39,40,41], while IL-23 inhibitors have proven effective in both Crohn’s disease and ulcerative colitis [42,43].